不同剂量PCSK9抑制剂治疗冠状动脉粥样硬化患者的效果比较OA

Objective To compare the effect of different doses of PCSK9 inhibitors on coronary atherosclerosis.Methods Sixty-six patients with coronary atherosclerosis admitted to Nanchang Third Hospital from August 2021 to August 2022 were selected as the study objects,and they were divided into high-dose group(n=33)and low-dose group(n=33)according to random number table method.Both groups received basic statin therapy:the high-dose group was given a PCSK9 inhibitor 450 mg once every 4 weeks,and the low-dose group was given a PCSK9 inhibitor 300 mg once every 4 weeks for 24 weeks.The clinical efficacy,blood lipid index and Gensini score were compared between the two groups.Results The total effective rate of high dose group was higher than that of low dose group,and the difference was statistically significant(P＜0.05).Af-ter treatment,the levels of triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and total cholesterol(TC)in two groups were lower than before treatment,and the levels of TG,LDL-C and TC in high-dose group were lower than those in low-dose group,with statistical significances(P＜0.05).After treatment,the Gensini score of the two groups was lower than that before treatment,and the Gensini score of the high-dose group was lower than that of the low-dose group,with statisti-cal significances(P＜0.05).Conclusion The curative effect of high-dose PCSK9 inhibitor is significant on patients with coronary atherosclerosis,which can regulate blood lipid metabolism and improve coronary stenosis.